DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR

Clinical trials for DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR explained in plain language.

Never miss a new study

Get alerted when new DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR trials appear

Sign up with your email to follow new studies for DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New hope for FSHD: experimental drug AOC 1020 tested in humans

Disease control Completed

This study tested an experimental drug called AOC 1020 in 90 adults with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease that causes progressive muscle weakness. The main goals were to check the drug's safety and how the body processes it. Participants recei…

Matched conditions: DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR

Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated May 01, 2026 16:00 UTC

DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR

Get alerted when new DYSTROPHY, FACIOSCAPULOHUMERAL MUSCULAR trials appear

New hope for FSHD: experimental drug AOC 1020 tested in humans